Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552305 · ClinicalTrials.gov registry record · Phase 2
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
A Phase 2 study of Partial Epilepsies, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
- 20
- Study locations
NCT00552305: Completed Phase 2 study of Partial Epilepsies, sponsored by UCB Pharma.
NCT00552305 is a Phase 2 study of Partial Epilepsies that has completed, run by UCB Pharma. The registered enrollment target is 370 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (178% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00552305, a Phase 2 study of Partial Epilepsies, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
Primary Outcome
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Conditions Studied
Interventions
- DRUG lacosamide
Study Locations (20)
Florida
- - Gainesville
- - Hollywood
- - Miami
- - Ponte Vedra Beach
Alabama
- - Birmingham
- - Huntsville
Arizona
- - Phoenix
- - Tucson
Illinois
- - Chicago
- - Springfield
Kentucky
- - Crestview Hills
- - Lexington
Maryland
- - Baltimore
- - Frederick
Arkansas
- - Little Rock
California
- - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2001-08 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00552305 record still lists
NCT00552305 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (178% higher).
The record links to 1 condition, with Partial Epilepsies appearing as the primary indexed condition, and to 1 intervention - of which lacosamide is the first listed.
NCT00552305 names 20 study sites across 12 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00552305 about?
NCT00552305 is a clinical study titled "To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures". The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
What is the current status of trial NCT00552305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2001-08. Estimated completion is 2010-02.
What conditions does trial NCT00552305 study?
This clinical trial studies the following conditions: Partial Epilepsies.
What interventions are being tested in trial NCT00552305?
The interventions under investigation include: lacosamide (DRUG).
Who is sponsoring clinical trial NCT00552305?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552305 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00552305's enrollment target sits among peer trials
370 120th of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia